Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled nitric oxide for prevention of primary graft dysfunction after lung transplantation
ChiCTR2300078778Phase 3Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Dec 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nitric oxide in primary graft dysfunction (PGD) (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Incidence of primary graft dysfunction grade 2/3 at 48 hours. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
nitric oxide
03
Conditions
primary graft dysfunction (PGD)
Beyond the preview
Go deeper on ChiCTR2300078778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078778.